>북미 좌심실 보조 장치(LVAD) 시장, 제품 유형(심장 펌프, 컨트롤러, 배터리 및 와이어), 치료(BTT(Bridge-To-Transplant) 치료, 목적지 치료, BTC(Bridge-To-Candidacy) 치료 및 BTR(Bridge-To-Recovery) 치료), 연령대(성인 및 소아), 적응증(울혈성 심부전, 선천적 심장병 , 심근염, 심장 마비, 가족성 부정맥 및 부정맥, 심근병증, 고도 심부전 및 기타), 세대(2세대 장치, 3세대 장치 및 1세대 장치), 내구성(장기, 중기 및 단기), 디자인(축 및 원심), 맥박 유형(비맥박 및 맥박), 최종 사용자(병원, 심장 카테터 실험실, 전문 클리닉 및 기타), 유통 채널(직접 입찰, 소매 판매 및 기타) - 업계 동향 및 2029년까지의 전망.
북미 좌심실 보조 장치(LVAD) 시장 분석 및 규모
좌심실 보조 장치(LVAD)는 심부전 환자에게 이식하는 기계적 펌프입니다. 심장의 왼쪽 하부 챔버(좌심실)가 심실에서 대동맥과 신체의 나머지 부분으로 혈액을 펌핑하도록 돕습니다. 말기 심부전에 도달한 환자에게 사용됩니다. LVAD는 수술적으로 이식하는 배터리로 작동하는 기계적 펌프로, 좌심실(심장의 주요 펌핑 챔버)이 신체의 나머지 부분으로 혈액을 펌핑하도록 돕습니다.
심혈관 질환의 발생은 빠른 속도로 증가하고 있습니다. 진행된 심혈관 고장은 북미 전체 인구의 약 2.3%에 영향을 미치고 심각한 사회경제적 부담으로 추산됩니다. 점점 더 매력적인 장치 개발을 목표로 하는 R&D 활동에 대한 강력한 강조와 최적의 정부 노력이 좌심실 보조 장치(LVAD) 시장을 주도하고 있습니다. 또한 캐나다 시장은 공급업체 환경에서 저강도 경쟁의 혜택을 볼 가능성이 높기 때문에 이 나라는 심실 보조 장치 분야에 진출하려는 기업에 매력적인 투자처가 될 것입니다. 이식을 위해 기증 심장을 기다리는 엄청난 수의 환자는 상업적 기회를 제공합니다. 그러나 LVAD 이식과 관련된 위험이 있으며 이러한 위험은 제약 요인으로 작용하여 시장 성장에 영향을 미칩니다. 또한 이 분야는 현재 DT 채택에 대한 장벽과 안전 문제를 포함한 여러 가지 과제에 직면해 있습니다.
북미 좌심실 보조 장치(LVAD) 시장은 2022년에서 2029년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년에서 2029년의 예측 기간 동안 9.5%의 CAGR로 성장하고 있으며 2029년까지 1,024.22백만 달러에 도달할 것으로 예상된다고 분석합니다. 좌심실 보조 장치의 기술적 발전이 증가함에 따라 좌심실 보조 장치(LVAD) 시장 성장이 촉진되고 있습니다.
|
보고서 메트릭 |
세부 |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customisable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
By Product Type (Heart Pump, Controller, Batteries, and Wires), Therapy (Bridge-To-Transplant (BTT) Therapy, Destination Therapy, Bridge-To-Candidacy (BTC) Therapy, and Bridge-To-Recovery (BTR) Therapy), Age Group (Adult and Pediatric), Indication (Congestive Heart Failure, Congenital Heart Disease, Myocarditis, Cardiac Arrest, Familial Arrhythmias and Arrhythmic, Cardiomyopathies, Advanced Heart Failure, and Others), Generation (Second Generation Devices, Third Generation Devices, and First Generation Devices), Durability (Long-Term, Intermediate-Term, and Short-Term), Design (Axial and Centrifugal), Pulse Type (Nonpulsatile and Pulsatile), End User (Hospitals, Cardiac Cath Laboratories, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) |
|
Countries Covered |
U.S., Canada, and Mexico |
|
Market Players Covered |
The major companies which are dealing in the market are ABIOMED, Abbott, Berlin Heart, Saft, Jarvik Heart, Inc., CorWave SA, and Evaheart, Inc., among others |
Market Definition
A left ventricular assist device (LVAD) is a mechanical pump implanted in patients with heart failure. It helps the left bottom chamber of the heart (left ventricle) pump blood out of the ventricle to the aorta and the rest of the body.
It is used for patients who have reached end-stage heart failure. The LVAD is surgically implanted, a battery-operated, mechanical pump, which helps the left ventricle (main pumping chamber of the heart) pump blood to the rest of the body. LVADs can be used as:
The high prevalence of cardiovascular diseases, increasing technological advancement, and rising healthcare expenditure are also propelling the growth of the North America left ventricular assist device (LVAD) market.
North America Left Ventricular Assist Device (LVAD) Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints and challenges. All of this is discussed in detail as below:
Drivers
- INCREASING GERIATRIC POPULATION, ALONG WITH THE RISING PREVALENCE OF CARDIAC DISEASES
The prevalence of cardiac diseases is also increasing with the growing geriatric population across North America. With an estimated 40 million blind individuals, most of them belong to the aged population. However, all the studies indicate a high prevalence of cardiac diseases in the geriatric population. With increasing age and the rising prevalence of cardiac disorders such as heart failure in the elderly population, proper treatment and medications are also rising. In addition, the growing population has increased the pressure on the healthcare system, due to which the need for care, services, and technologies is rising rapidly. Therefore, the increasing geriatric population is expected to drive North America left ventricular assist device (LVAD) market.
- PRESENCE OF FAVOURABLE REIMBURSEMENT POLICIES
The Centers for Medicare & Medicaid Services (CMS) has published a decision memorandum liberalizing criteria for coverage of ventricular assist devices (CMS, 2010). The CMS policy removes body size criteria and eases restrictions around the required duration of failed medical therapy and peak oxygen consumption. Henceforth, favorable reimbursement policies are expected to drive North America left ventricular assist device (LVAD) market in the forecast year.
Opportunities
- INCREASE IN HEALTHCARE EXPENDITURE
Healthcare expenditure has increased in North America as disposable income in the countries is increasing. Moreover, to accomplish the population requirements, the government bodies and healthcare organizations are taking initiatives by accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for various cardiovascular conditions and provide surgical treatment as the disorder has been highly prevalent in recent years.
The rise in healthcare expenditure has given the market an opportunity by providing more treatment options, free diagnostics, and different programs for promoting early diagnosis. Moreover, the healthcare expenditure by the government is focused on allocating resources towards strategies to improve management and patient outcomes to lower the growing economic burden.
Growing healthcare expenditure is also beneficial for further economic growth and healthcare sector growth, and it is primarily fruitful as it significantly affects the development of better and more advanced devices for such cardiology conditions. Thereby surge in healthcare expenditure is a greater opportunity for North America left ventricular assist device (LVAD) market.
Restraints/Challenges
- HIGH COST OF LVAD IMPLANTATION AND TREATMENT
LVADs in non-inotrope-dependent heart failure patients improve quality of life but substantially increase lifetime costs because of frequent readmissions and costly follow-up care. Left ventricular assist devices also increase employment and career, affecting finances.
The high cost of LVAD implantation and treatment poses a financial burden and challenges for a patient. Moreover, the high cost of follow-up care further increases the financial burden on the patient, which restrains the growth of the market.
This North America Left Ventricular Assist Device (LVAD) Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.
Recent Development
- On December 21, 2020, the U.S. Food and Drug Administration (FDA) approved updated labeling on December 17 for Abbott's HeartMate 3 left ventricular assist device (LVAD) to be used in pediatric patients with advanced refractory left ventricular heart failure
North America Left Ventricular Assist Device (LVAD) Market Scope
North America left ventricular assist device (LVAD) market is categorized into ten notable segments based on product type, therapy, age group, indication, generation, durability, design, pulse type, end-user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.
BY PRODUCT TYPE
- HEART PUMP
- CONTROLLER
- BATTERIES
- WIRES
On the basis of product type, North America left ventricular assist device (LVAD) market is segmented into heart pump, controller, batteries, and wires. Batteries are further segmented into rechargeable and non-rechargeable.
BY THERAPY
- Bridge-To-Transplant (BTT) Therapy
- Destination Therapy
- Bridge-To-Candidacy (BTC) Therapy
- Bridge-To-Recovery (BTR) Therapy
On the basis of therapy, North America left ventricular assist device (LVAD) market is segmented bridge-to-transplant (BTT) therapy, destination therapy, bridge-to-candidacy (BTC) therapy, and bridge-to-recovery (BTR) therapy.
BY AGE GROUP
- Adult
- PAEDIATRIC
On the basis of age group, North America left ventricular assist device (LVAD) market is segmented into adult and paediatric.
BY INDICATION
- Congestive Heart Failure
- Congenital Heart Disease
- Myocarditis
- Cardiac Arrest
- Familial Arrhythymias and Arrhythmic
- Cardiomyopathies
- Advanced Heart Failure
- Others
On the basis of indication, North America left ventricular assist device (LVAD) market is segmented into congestive heart failure, congenital heart disease, myocarditis, cardiac arrest, familial arrhythymias and arrhythmic cardiomyopathies, advanced heart failure, and others.
BY GENERATION
- Second Generation Devices
- Third Generation Devices
- First Generation Devices
On the basis of generation, North America left ventricular assist device (LVAD) market is segmented into second-generation devices, third-generation devices, and first-generation devices.
BY DURABILITY
- Long-Term
- Intermediate-Term
- Short-Term
On the basis of durability, North America left ventricular assist device (LVAD) market is segmented into long-term, intermediate-term, and short-term.
BY DESIGN
- Axial
- Centrifugal
On the basis of design, North America left ventricular assist device (LVAD) market is segmented into axial and centrifugal.
BY PULSE TYPE
- Nonpulsatile
- Pulsatile
On the basis of pulse type, North America left ventricular assist device (LVAD) market is segmented into non-pulsatile and pulsatile.
BY END USER
- Hospitals
- Cardiac Cath Laboratories
- Specialty Clinics
- Others
최종 사용자를 기준으로 북미 좌심실 보조 장치(LVAD) 시장은 병원, 전문 클리닉, 심장 카테터 검사실 및 기타로 구분됩니다.
유통 채널별
- 직접 입찰
- 소매 판매
- 기타
유통 채널을 기준으로 북미 좌심실 보조 장치(LVAD) 시장은 직접 입찰, 소매 판매 및 기타로 구분됩니다.
북미 좌심실 보조 장치(LVAD) 시장 지역 분석/통찰력
북미 좌심실 보조 장치(LVAD) 시장을 분석하고, 위에 언급된 대로 국가, 제품 유형, 치료법, 연령대, 적응증, 세대, 내구성, 디자인, 펄스 유형, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.
북미 좌심실 보조 장치(LVAD) 시장은 미국, 캐나다, 멕시코와 같은 국가를 포함하며 심장 질환 사례 증가와 노령 인구 증가로 인해 성장할 것으로 예상됩니다. 심실 질환 위험 증가도 시장 성장을 견인하고 있습니다.
미국은 첨단 기술, 심장 질환의 높은 유병률, 확립된 의료 시스템의 존재로 인해 북미 좌심실 보조 장치(LVAD) 시장을 지배할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변경 사항을 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 다른 브랜드의 존재 및 가용성과 지역 및 국내 브랜드의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 좌심실 보조 장치(LVAD) 시장 점유율 분석
북미 좌심실 보조 장치(LVAD) 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 국가적 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 포함됩니다. 위에 제공된 데이터 포인트는 골다공증 약물 시장과 관련된 회사의 초점에만 관련이 있습니다.
북미 좌심실 보조 장치(LVAD) 시장의 주요 기업으로는 ABIOMED, Abbott, Berlin Heart, Saft, Jarvik Heart, Inc., CorWave SA, Evaheart, Inc. 등이 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S
4.3 INDUSTRIAL INSIGHTS:
5 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: REGULATIONS
5.1 REGULATION IN U.S.
5.1.1 GUIDELINES-
5.2 REGULATION IN CANADA
5.2.1 GUIDELINES FOR THE MANUFACTURERS:
5.3 REGULATION IN MEXICO
5.3.1 GUIDELINES FOR THE MANUFACTURERS:
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING GERIATRIC POPULATION ALONG WITH RISING PREVALENCE OF CARDIAC DISEASES
6.1.2 PRESENCE OF FAVOURABLE REIMBURSEMENT POLICIES
6.1.3 CHANGING LIFESTYLE TRIGGERS THE DEVELOPMENT OF CARDIOVASCULAR DISEASES
6.2 RESTRAINTS
6.2.1 HIGH COST OF LVAD IMPLANTATION AND TREATMENT
6.2.2 COMPLICATIONS AND RISKS ASSOCIATED WITH LVAD
6.3 OPPORTUNITIES
6.3.1 INCREASE IN HEALTHCARE EXPENDITURE
6.3.2 INCREASE IN MINIMALLY INVASIVE PROCEDURE
6.3.3 INCREASING SHORTAGE OF ORGAN DONORS
6.3.4 TECHNOLOGICAL ADVANCEMENTS IN LEFT VENTRICULAR ASSIST DEVICES
6.4 CHALLENGES
6.4.1 ONGOING COVID-19
6.4.2 INCREASE IN PRODUCT RECALL
7 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 HEART PUMP
7.3 CONTROLLER
7.4 BATTERIES
7.4.1 RECHARGEABLE
7.4.2 NON-RECHARGEABLE
7.5 WIRES
8 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY
8.1 OVERVIEW
8.2 BRIDGE-TO-TRANSPLANT (BTT) THERAPY
8.2.1 HEART PUMP
8.2.2 CONTROLLER
8.2.3 BATTERIES
8.2.4 WIRES
8.3 DESTINATION THERAPY
8.3.1 HEART PUMP
8.3.2 CONTROLLER
8.3.3 BATTERIES
8.3.4 WIRES
8.4 BRIDGE-TO-CANDIDACY (BTC) THERAPY
8.4.1 HEART PUMP
8.4.2 CONTROLLER
8.4.3 BATTERIES
8.4.4 WIRES
8.5 BRIDGE-TO-RECOVERY (BTR) THERAPY
8.5.1 HEART PUMP
8.5.2 CONTROLLER
8.5.3 BATTERIES
8.5.4 WIRES
9 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY AGE GROUP
9.1 OVERVIEW
9.2 ADULT
9.2.1 19-39 YEARS
9.2.2 40-59 YEARS
9.2.3 60-79 YEARS
9.2.4 ABOVE 80 YEARS
9.3 PEDIATRIC
10 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY GENERATION
10.1 OVERVIEW
10.2 SECOND GENERATION DEVICES
10.3 THIRD GENERATION DEVICES
10.4 FIRST GENERATION DEVICES
11 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DESIGN
11.1 OVERVIEW
11.2 AXIAL
11.3 CENTRIFUGAL
12 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION
12.1 OVERVIEW
12.2 CONGESTIVE HEART FAILURE
12.2.1 HEART PUMP
12.2.2 CONTROLLER
12.2.3 BATTERIES
12.2.4 WIRES
12.3 CONGENITAL HEART DISEASE
12.3.1 HEART PUMP
12.3.2 CONTROLLER
12.3.3 BATTERIES
12.3.4 WIRES
12.4 MYOCARDITIS
12.4.1 HEART PUMP
12.4.2 CONTROLLER
12.4.3 BATTERIES
12.4.4 WIRES
12.5 CARDIAC ARREST
12.5.1 HEART PUMP
12.5.2 CONTROLLER
12.5.3 BATTERIES
12.5.4 WIRES
12.6 FAMILIAL ARRHYTHMIAS AND ARRHYTHMIC CARDIOMYOPATHIES
12.6.1 HEART PUMP
12.6.2 CONTROLLER
12.6.3 BATTERIES
12.6.4 WIRES
12.7 ADVANCED HEART FAILURE
12.7.1 HEART PUMP
12.7.2 CONTROLLER
12.7.3 BATTERIES
12.7.4 WIRES
12.8 OTHERS
13 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY DURABILITY
13.1 OVERVIEW
13.2 LONG-TERM
13.3 INTERMEDIATE-TERM
13.4 SHORT-TERM
14 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY PULSE TYPE
14.1 OVERVIEW
14.2 NONPULSATILE
14.3 PULSATILE
15 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITAL
15.3 CARDIAC CATH LABORATORIES
15.4 SPECIALTY CLINICS
15.5 OTHERS
16 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.4 OTHERS
17 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY NORTH AMERICA
17.1 NORTH AMERICA
17.1.1 U.S.
17.1.2 CANADA
17.1.3 MEXICO
18 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 ABIOMED
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.1.5.1 FDA APPROVAL
20.1.5.2 FDA APPROVAL
20.2 ABBOTT
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.2.5.1 SUPPLY INCREMENT
20.2.5.2 BREAK THROUGH DEVICE DESIGNATION
20.3 BERLIN HEART
20.3.1 COMPANY SNAPSHOT
20.3.2 COMPANY SHARE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENT
20.3.4.1 PRODUCT APPROVAL
20.4 SAFT (A SUBSIDIARY OF TOTALENERGIES)
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENT
20.4.5.1 PARTNERSHIP
20.5 JARVIK HEART, INC.
20.5.1 COMPANY SNAPSHOT
20.5.2 COMPANY SHARE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.5.4.1 FDA APPROVAL
20.6 CORWAVE SA
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.6.3.1 EXPANSION
20.7 EVAHEART, INC
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.7.3.1 PRODUCT TRIAL
21 QUESTIONNAIRE
22 RELATED REPORTS
표 목록
TABLE 1 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA BATTERIES IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA BATTERIES IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA BRIDGE-TO-TRANSPLANT (BTT) THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA DESTINATION THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA BRIDGE-TO-CANDIDACY (BTC) THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA BRIDGE-TO-RECOVERY (BTR) THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA ADULT IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY GENERATION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA CONGESTIVE HEART FAILURE IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA CONGENITAL HEART DISEASE IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA MYOCARDITIS IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA CARDIAC ARREST IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA FAMILIAL ARRHYTHMIAS AND ARRHYTHMIC CARDIOMYOPATHIES IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA ADVANCED HEART FAILURE IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DURABILITY, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PULSE TYPE, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 24 U.S. LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 25 U.S. LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 26 U.S. BATTERIES IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 27 U.S. LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 28 U.S. BRIDGE-TO-TRANSPLANT (BTT) THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 29 U.S. DESTINATION THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 30 U.S. BRIDGE-TO-CANDIDACY (BTC) THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 31 U.S. BRIDGE-TO-RECOVERY (BTR) THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 32 U.S. LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 33 U.S. ADULT IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 34 U.S. LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 35 U.S. CONGESTIVE HEART FAILURE IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 36 U.S. CONGENITAL HEART DISEASE IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 37 U.S. MYOCARDITIS IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 38 U.S. CARDIAC ARREST IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 39 U.S. FAMILIAL ARRHYTHMIAS AND ARRHYTHMIC CARDIOMYOPATHIES IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 40 U.S. ADVANCED HEART FAILURE IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 41 U.S. LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY GENERATION, 2020-2029 (USD MILLION)
TABLE 42 U.S. LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DURABILITY, 2020-2029 (USD MILLION)
TABLE 43 U.S. LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 44 U.S. LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PULSE TYPE, 2020-2029 (USD MILLION)
TABLE 45 U.S. LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 46 U.S. LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 47 CANADA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 48 CANADA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 49 CANADA BATTERIES IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 50 CANADA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 51 CANADA BRIDGE-TO-TRANSPLANT (BTT) THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 52 CANADA DESTINATION THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 53 CANADA BRIDGE-TO-CANDIDACY (BTC) THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 54 CANADA BRIDGE-TO-RECOVERY (BTR) THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 55 CANADA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 56 CANADA ADULT IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 57 CANADA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 58 CANADA CONGESTIVE HEART FAILURE IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 59 CANADA CONGENITAL HEART DISEASE IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 60 CANADA MYOCARDITIS IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 61 CANADA CARDIAC ARREST IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 62 CANADA FAMILIAL ARRHYTHMIAS AND ARRHYTHMIC CARDIOMYOPATHIES IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 63 CANADA ADVANCED HEART FAILURE IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 64 CANADA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY GENERATION, 2020-2029 (USD MILLION)
TABLE 65 CANADA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DURABILITY, 2020-2029 (USD MILLION)
TABLE 66 CANADA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 67 CANADA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PULSE TYPE, 2020-2029 (USD MILLION)
TABLE 68 CANADA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 69 CANADA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 70 MEXICO LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 71 MEXICO LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 72 MEXICO BATTERIES IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 73 MEXICO LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 74 MEXICO BRIDGE-TO-TRANSPLANT (BTT) THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 75 MEXICO DESTINATION THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 76 MEXICO BRIDGE-TO-CANDIDACY (BTC) THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 77 MEXICO BRIDGE-TO-RECOVERY (BTR) THERAPY IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY, 2020-2029 (USD MILLION)
TABLE 78 MEXICO LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 79 MEXICO ADULT IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 80 MEXICO LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 81 MEXICO CONGESTIVE HEART FAILURE IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 82 MEXICO CONGENITAL HEART DISEASE IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 83 MEXICO MYOCARDITIS IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 84 MEXICO CARDIAC ARREST IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 85 MEXICO FAMILIAL ARRHYTHMIAS AND ARRHYTHMIC CARDIOMYOPATHIES IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 86 MEXICO ADVANCED HEART FAILURE IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 87 MEXICO LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY GENERATION, 2020-2029 (USD MILLION)
TABLE 88 MEXICO LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DURABILITY, 2020-2029 (USD MILLION)
TABLE 89 MEXICO LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DESIGN, 2020-2029 (USD MILLION)
TABLE 90 MEXICO LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PULSE TYPE, 2020-2029 (USD MILLION)
TABLE 91 MEXICO LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 92 MEXICO LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: NORTH AMERICA VS REGIONAL ANALYSIS
FIGURE 5 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET:VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASE AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 HEART PUMP SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET
FIGURE 14 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY PRODUCT TYPE, 2021
FIGURE 15 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY PRODUCT TYPE, 2020-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY PRODUCT TYPE, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY THERAPY, 2021
FIGURE 19 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY THERAPY, 2020-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY THERAPY, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY THERAPY, LIFELINE CURVE
FIGURE 22 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY AGE GROUP, 2021
FIGURE 23 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY AGE GROUP, 2020-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 26 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY GENERATION, 2021
FIGURE 27 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY GENERATION, 2020-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY GENERATION, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY GENERATION, LIFELINE CURVE
FIGURE 30 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY DESIGN, 2021
FIGURE 31 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY DESIGN, 2020-2029 (USD MILLION)
FIGURE 32 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY DESIGN, CAGR (2022-2029)
FIGURE 33 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY DESIGN, LIFELINE CURVE
FIGURE 34 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY INDICATION, 2021
FIGURE 35 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY INDICATION, 2020-2029 (USD MILLION)
FIGURE 36 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY INDICATION, CAGR (2022-2029)
FIGURE 37 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 38 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY DURABILITY, 2021
FIGURE 39 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY DURABILITY, 2020-2029 (USD MILLION)
FIGURE 40 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY DURABILITY, CAGR (2022-2029)
FIGURE 41 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY DURABILITY, LIFELINE CURVE
FIGURE 42 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY PULSE TYPE, 2021
FIGURE 43 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY PULSE TYPE, 2020-2029 (USD MILLION)
FIGURE 44 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY PULSE TYPE, CAGR (2022-2029)
FIGURE 45 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY PULSE TYPE, LIFELINE CURVE
FIGURE 46 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY END USER, 2021
FIGURE 47 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 48 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY END USER, CAGR (2022-2029)
FIGURE 49 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY END USER, LIFELINE CURVE
FIGURE 50 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 51 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 52 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 53 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 54 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: SNAPSHOT (2021)
FIGURE 55 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY COUNTRY (2021)
FIGURE 56 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 57 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 58 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: BY PRODUCT TYPE (2022-2029)
FIGURE 59 NORTH AMERICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
